GlassScriptPhysician profile
Chadwick Reginald Brasington
NPI 1033132923
$5,482.75
in general payments reported to CMS, 2019-2025
31 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $250 · 2021: $385 · 2022: $1,028 · 2023: $1,232 · 2024: $1,227 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,328.64 | 2022-2025 | |
| Alcon Vision LLC | $775.49 | 2019-2025 | Clareon, Tryptyr, Lensx |
| Notal Vision, INC. | $712.13 | 2023-2024 | Foresee Home |
| Mallinckrodt Hospital Products INC. | $371.92 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $345.65 | 2019-2022 | |
| Oyster Point Pharma, INC. | $286.29 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $280.65 | 2022-2024 | Alphagan P, Lumigan, Vuity |
| Allergan, INC. | $194.13 | 2019-2022 | |
| Dompe US, INC. | $140.14 | 2019-2025 | Oxervate |
| Genentech USA, INC. | $120.89 | 2022-2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $114.45 | 2022-2024 | Miebo, Toric, Envista Mx60 Iol |
| Tarsus Pharmaceuticals, INC. | $107.22 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $94.18 | 2019-2021 | |
| Harrow Eye, LLC | $74.26 | 2025 | Vevye |
| Amgen INC. | $68.71 | 2024-2025 | Tepezza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $63.68 | 2019 | |
| Shire North American Group INC | $51.85 | 2019 | |
| Apellis Pharmaceuticals, INC. | $43.93 | 2023 | Syfovre |
| Sun Pharmaceutical Industries INC. | $42.35 | 2019-2024 | |
| Ocular Therapeutix, INC. | $37.38 | 2019-2023 | Dextenza |
| Thea Pharma INC. | $36.27 | 2022-2024 | Iyuzeh |
| Sight Sciences, INC. | $29.54 | 2019-2023 | Omni Surgical System |
| Merz North America, INC. | $28.95 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $26.35 | 2025 | Forum |
| Coherus Oncology, INC. | $26.21 | 2023 | |
| Glaukos Corporation | $24.90 | 2024 | Idose |
| Johnson & Johnson Surgical Vision, INC. | $14.16 | 2025 | |
| Tearlab Corp | $14.05 | 2024 | Scoutpro Osmolarity System |
| Aerie Pharmaceuticals, INC. | $13.22 | 2019 | |
| Kala Pharmaceuticals, INC. | $12.60 | 2019 | |
| Heron Therapeutics, INC. | $2.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadwick Brasington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.